Friday Hope: Degrading the Spike Protein: Neanthes japonica (Izuka)
Interestingly, the enzyme from Izuka is also fibrinolytic and neuroprotective in reperfusion.
Degradation of S protein, S1 protein, and RBD-mouseFc by ASPNJ of different concentrations: (a) degradation of S; (b) degradation of S1; and (c) degradation of RBD-mouseFc (Rm). The concentration of S, S1, and Rm were all 10 μg/lane. A1–A5 were ASPNJ/lanes of different concentrations (A1–A5 were 50 (or 30), 1, 0.2, 0.04, 0.008 μg/lane, respectively). Each of the three proteins was degraded by ASPNJ, with a total volume of 25 μL, at 40 °C for 60 min, and the degradation effect was observed by running SDS-PAGE.
As readers of this Substack know, I believe the path forward for resolution of Spike Protein induced disease and injury is twofold: 1) To remove the Spike Protein from the body. 2) To rebuild the damaged/destroyed tissues it has left in its wake.
Much has been written about several compounds which show promise in being able to degrade the Spike Protein. However, I have found one compound which should prove to be the Gold Standard in removing the Spike Protein from the body.
Meet Neanthes japonica (Izuka).
Neanthes japonica, a polychaete, is a euryhaline species native to China and Japan. It is widely present in estuarine systems, living as a deposit-feeder near the surface of sedimentary deposits rich in bio-detritus. Due to its high nutritional value, it is considered as high-quality food for many aquatic organisms, such as fish and crustaceans, and is used as bait in sea fishing. In addition, it has been widely recognized as an ideal feed for shrimp aquaculture. N. japonica is shrimp bait and provides a suitable living environment for the growth of shrimp through bioturbation. For N. japonica, some papers have focused on the purification and characterization of fibrinolytic enzymes from N. japonica in recent years.
Bacterial Community in the Gut of Neanthes japonica and Its Association with Surrounding Environment
https://www.mdpi.com/1424-2818/14/7/514
It is these fibrinolytic enzymes which should prove most valuable.
And, yes, it is a marine worm.
Polychaeta (/ˌpɒlɪˈkiːtə/) is a paraphyletic class of generally marine annelid worms, commonly called bristle worms or polychaetes (/ˈpɒlɪˌkiːts/).
Polychaete
https://en.wikipedia.org/wiki/Polychaete
The fibrinolytic enzyme purified from Neanthes japonica (NJ) was first labeled as NJF. As you will read, it has the ability to treat two major pathological conditions caused by the Spike Protein. It dissolves fibrin and fibrinogen (clots) and offers neuroprotection from reperfusion, which my previous research has shown to be a major cause of injury by the Spike Protein. It also inhibits lipid peroxidation and increases endogenous antioxidant defense enzymes.
Thrombolytic agent is increasingly being used in treating acute ischemic stroke. A novel protease with strong thrombolytic activity, Neanthes japonica (Iznka) fibrinolytic enzyme (NJF) discovered in our laboratory has been reported with characteristics of direct hydrolyzing fibrin and fibrinogen. The neuroprotective effect of NJF and urokinase (UK) was tested in rat models of middle cerebral artery occlusion (MCAO). The model was successfully produced by introducing an intraluminal suture into the left middle cerebral artery (MCA). NJF (0.25, 0.5, 1mg/kg) was injected intravenously 1h after the onset of reperfusion. Compared with vehicle group, MCAO animals treated with NJF showed dose dependent reduction in cerebral infarction with improved neurological outcome. Meanwhile, ischemia induced cerebral edema was reduced in a dose dependent manner. Treatment with NJF at 0.5mg/kg was almost equivalent to UK at 15,000U/kg dosage in the reduction of cerebral infarction and cerebral edema. Biomedical assay showed that NJF treatment suppressed lipid peroxidation and restored superoxide dismutase (SOD) activities in brain tissue. These results suggest that NJF posses neuroprotective potential in rat MCAO and reperfusion model. Neuroprotection shown by NJF may be attributed to inhibition of lipid peroxidation, increase in endogenous antioxidant defense enzymes.
Neanthes japonica (Iznka) fibrinolytic enzyme reduced cerebral infarction, cerebral edema and increased antioxidation in rat models of focal cerebral ischemia
https://pubmed.ncbi.nlm.nih.gov/21129442/
This enzyme also has another superb quality. It rapidly degrades the Spike Protein (please see figure above). It also appears to degrade the Spike Protein in variants while have low toxicity to cells.
The alkaline serine protease with an acidic pI (ASPNJ) was previously purified from Neanthes japonica (Izuka) and characterized in our lab, formerly named NJF.
Therefore, the aa mutation of the variants did not significantly increase the number of NCS in the S protein, especially in the RBD and CendR motifs. At the same time, the aa mutation of the S protein of different variants increased the pI of the S, S1, and RBD regions. The increased pI can enhance the polar interaction between RBD and ACE2 receptors, but it also enhances the interaction between the S protein and ASPNJ, thereby promoting the degradation of S, S1, and RBD by ASPNJ. Therefore, just as ASPNJ acts on the SARS-CoV-2 wild-type strain, it may similarly degrade the S or S1 protein of variants.
ASPNJ has the advantages of low toxicity to normal host cells as well as no hemolysis or agglutination of human red blood cells in vivo and in vitro [18,19]. In intravenous injection experiments, no toxicity or damage was observed to the liver, kidney, and cardiovascular system of mice, rats, rabbits, and beagle dogs, and the LD50 of mice was 20 mg/kg body weight (unpublished data). In addition, ASPNJ is relatively stable. The enzyme activity is stable in the range of 40~80 °C and pH 6~11. Its maximum enzymatic activity was observed at 60 °C and pH 9.0. ASPNJ was purified and stored as a lyophilized powder at −20 °C. Its fibrinolytic activity can even be maintained for more than 10 years. We hypothesize that ASPNJ in vivo experiments may degrade the virus S protein and at the same time, it may be beneficial to the improvement of patients with coagulation dysfunction.
Rapid Degradation of SARS-CoV-2 Spike S Protein by A Specific Serine Protease
https://www.mdpi.com/1420-3049/27/6/1882
In all of my research, this currently holds the most promise for removing the Spike Protein from the body. More testing and research is certainly needed. If this proves true, then we have reached a milestone in resolving the suffering caused by this most malevolent protein.
Happy New Year to all! Your support allows me to continue my work. I cannot express my thanks in any better way than to continue to work. Blessings and great hope for the year to come.
Is this much different from Nattokinase in fibrinolytic activity?
Happy New Year Walter!